Insights

Outsourced Pharma Capacity 2024 - Curia Biologics

icons/content-types/video webinar

Biologics

Watch as our Vice President of Biologics, Steve Lavezoli, explains how we’ve been a critical partner for biotech businesses of all sizes—small, midsize, and even large—supporting their needs from IND-enabling studies through late-stage commercial programs.



Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

icons/content-types/video webinar

Antibody-Drug Conjugate (ADC) – From Bioassay Development to Linker-Payload Constructs

In this webinar, we will discuss select examples of Curia’s experience in the ADC discovery space and how some of these challenges are overcome.

icons/content-types/article article

Accelerating Therapies With Curia From Conception to Manufacturing

Partnering with a CDMO can help streamline drug development, and certain preparations can help ensure a successful collaboration. Scott Alderucci, Curia’s Director of Process Development, explores the advantages of partnering with a CDMO to navigat...